Measurement of NK activity by the microcytotoxicity assay (MCA): a new application for an old assay

B J Wahlberg1, D R Burholt, P Kornblith

  • 1Department of Pharmacology, University of Pittsburgh School of Medicine, 15213, Pittsburgh, PA, USA.

Insights

Natural killer (NK) cells kill tumor cells via necrotic or apoptotic pathways. A new modified cell assay (MCA) measures apoptotic killing, revealing reduced NK cell activity in breast cancer patients, unlike standard assays.

Area of Science:

  • Immunology
  • Cell Biology
  • Cancer Research

Background:

  • Natural killer (NK) cells are crucial immune cells that eliminate tumor cells through distinct cytotoxic pathways: perforin/granzyme-mediated necrosis and TNF ligand-mediated apoptosis.
  • Current methods, like the chromium-51 release assay (CRA), reliably measure necrotic killing but lack standardized, high-throughput assays for apoptotic killing.
  • This gap limits the comprehensive assessment of NK cell function, particularly in disease contexts where apoptotic pathways may be more relevant.

Purpose of the Study:

  • To introduce and validate a modified cell assay (MCA) for measuring perforin/granzyme-independent, NK cell-mediated apoptotic killing of tumor cells.
  • To compare the sensitivity and clinical relevance of MCA with the standard CRA for assessing NK cell activity.
  • To investigate NK cell activity in breast cancer patients using both MCA and CRA.

Main Methods:

  • The modified cell assay (MCA) utilizes adherent tumor cell targets in microwells, co-incubated with peripheral blood mononuclear leukocytes (PBMNL) for 24 hours.
  • Viable, adherent tumor cells are quantified after washing away non-adherent dead cells, allowing measurement of NK cell-induced apoptosis.
  • NK cell activity was assessed in parallel using MCA and the standard chromium release assay (CRA) in healthy donors and breast cancer patients.

Main Results:

  • The MCA demonstrated dose-dependent, time-dependent, and donor-dependent killing of tumor cells, mediated exclusively by CD3(-)CD56(+)CD16(+) NK cells.
  • No significant correlation was found between NK cell activities measured by MCA and CRA in healthy individuals or breast cancer patients.
  • While CRA showed normal NK activity in most breast cancer patients, MCA revealed significantly decreased NK cell-mediated apoptotic killing in a majority of patients.

Conclusions:

  • The modified cell assay (MCA) provides a sensitive, high-throughput, and practical method for measuring NK cell-mediated apoptotic killing.
  • MCA assesses a distinct biological mechanism of NK cell cytotoxicity compared to CRA, highlighting its potential clinical relevance.
  • The reduced NK cell apoptotic activity observed via MCA in breast cancer patients suggests this pathway's importance in cancer immunology and diagnostics.

Related Concept Videos